Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.39

€0.39

5.950%
0.022
5.950%
-
 
05.02.26 / Frankfurt WKN: A3D51F / Name: Thiogenesis Therapeutics Corp. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Thiogenesis Therapeutics Corp. Stock

A very strong showing by Thiogenesis Therapeutics Corp. today, with an increase of €0.022 (5.950%) compared to yesterday's price.

Pros and Cons of Thiogenesis Therapeutics Corp. in the next few years

Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026

Highlighting Optimized Once-Daily Weight-Based Dosing and Clinically Meaningful Fatigue Improvement

 

San Diego, California – January 23, 2026 – Thiogenesis Therapeutics, Corp. (TSXV: TTI)

Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis

Trial achieved biological proof-of-concept, dose discovery and biomarker improvement

 

San Diego, California, November 4, 2025Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)